Peptide inhibitors of virus—cell fusion: enfuvirtide as a case study in clinical discovery and development
- 1 July 2004
- journal article
- review article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 4 (7) , 426-436
- https://doi.org/10.1016/s1473-3099(04)01058-8
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtideJournal of the American Academy of Dermatology, 2003
- Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 WeeksHIV Research & Clinical Practice, 2003
- The structural biology of type I viral membrane fusionNature Reviews Molecular Cell Biology, 2003
- Subcutaneous Injection Survey: Psychometric Evaluation of a Treatment Satisfaction Instrument Associated with a Novel HIV MedicationHIV Research & Clinical Practice, 2002
- Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformationJournal of Molecular Biology, 2000
- LearnCoil-VMF: computational evidence for coiled-coil-like motifs in many viral membrane-fusion proteinsJournal of Molecular Biology, 1999
- Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.Proceedings of the National Academy of Sciences, 1996
- Furin is important but not essential for the proteolytic maturation of gp160 of HIV‐1FEBS Letters, 1995
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Morphogenesis and morphology of HIV structure-function relationsArchiv für die gesamte Virusforschung, 1989